Abstract：Objective To investigate the clinical efficacy of Butylphthalide combined with Sodium Ozagrel in the treatment of acute severe cerebral infarction. Methods In this study, 204 patients with acute severe cerebral infarction treated in the Jizhou District Hospital from January 2014 to January 2016 were analyzed retrospectively. They were divided into observation group (120 cases) and control group (84 cases) according to clinical treatment methods. Patients in the control group were treated with basic treatment combined with Sodium Ozagrel, while patients in the observation group were treated with Butylphthalide based on the control group. They were treated for 1 week. The serum cholinesterase (CHE), interleukin-6 (IL-6) and the rate of ECG change before and after treatment were observed. The national institutes of health (NIHSS) score and Glasgow coma (GCS) were wsed to compare the clinical efficacy of the two groups. Results After treatment, the GCS scores and CHE levels were increased (P < 0.05), NIHSS scores and the IL-6 levels were decreased (P < 0.05), while the improvement of the observation group was more remarkable than control group (P < 0.05). Besides, the rate of abnormal ECG change was lower than that of the control group (P < 0.05). Conclusion The combination of Butyphthalide and Sodium Ozagrel in treating acute severe cerebral infarction can effectively increase the serum cholinesterase level, down-regulate the level of IL-6, reduce the incidence of ECG abnormalities and improve the curative effect of neurological deficits.
2018, Vol. 15 
京公网安备 11010502046598号